Advertisement

Most Americans unwilling to join clinical trials, study finds

Nearly half of healthcare consumers and more than half of doctors are apprehensive about participating in a clinical trial for cancer treatment.

By
Stephen Feller
Most drugs brought to the market are put through extensive clinical trials to establish their efficacy and safety, but both patients and their doctors are hesitant to consider them as part of cancer treatment, according to a study by Memorial Sloan Kettering Cancer Center. Photo by Milena Ugrinova/Shutterstock
Most drugs brought to the market are put through extensive clinical trials to establish their efficacy and safety, but both patients and their doctors are hesitant to consider them as part of cancer treatment, according to a study by Memorial Sloan Kettering Cancer Center. Photo by Milena Ugrinova/Shutterstock

NEW YORK, May 24 (UPI) -- Just over one-third of Americans are willing to participate in a clinical trial, and more than half of doctors do not consider recommending clinical trials until later in treatment, according to a recent survey.

Researchers at Memorial Sloan Kettering Cancer Center, which has nearly 1,000 clinical trials currently underway, found difficulty enrolling patients in trials for new drugs is based on the misconceptions of patients and apprehension of doctors.

Advertisement

Before drugs are brought to market, they go through often exhaustive clinical trials to test efficacy against disease and find potential side effects.

Patients are equal parts nervous about trying an unproven drug and being given a placebo, which means they will not actually be treated, but when educated briefly on trials -- such as that most cancer drug trials do not involve placebo groups -- their opinion improved significantly.

RELATED CDC: More people quit smoking in 2015 than in decades

"Failing to consider clinical trials at every stage of cancer diagnosis and treatment can represent a significant missed opportunity, primarily for patients, as well as for doctors and researchers trying to develop better therapies," Dr. Paul Sabbatini, depute physician-in-cheif for clinical research at Memorial Sloan-Kettering Cancer Center, said in a press release. "It's critical that we spread the word: Clinical trials offer our best thinking toward finding better ways to prevent, treat, and cure cancer, and there are options for patients and their families to consider early on in treatment."

For the survey, researchers for Sloan Kettering interviewed 1,511 healthcare consumers between age 18 and 69, as well as 594 doctors who have discussed clinical trials with their patients.

The researchers found 35 percent of consumers are "likely" to enroll in a clinical trial, and just 40 percent have an overall positive view of trials.

RELATED Study: Extreme beliefs often mistaken for insanity in criminal cases

Among consumers hesitant to participate in a trial, 55 percent are worried about side effects and safety, 50 percent are uncertain about insurance or out-of-pocket costs, 48 percent found trial locations are inconvenient, 46 percent worried about getting a placebo, 35 percent were concerned about drug treatments not proven to be effective and 34 percent did not want to feel like a guinea pig.

Doctors share some concerns with their patients about trials, with 56 percent saying they do not consider them until late in treatment and 28 percent calling them a "last resort" option. Just under one-third, 32 percent, of doctors said they discuss trials that could potentially help their patients at the beginning of treatment.

Among doctors, 63 percent were concerned about safety in trials, 63 percent were worried about patients receiving placebo rather than treatment and 53 percent were worried their patients would feel like guinea pigs.

RELATED Low-income children receive sub-par care for brain injuries, study says

"When it comes to advancing cancer care, clinical research is the rocket fuel for better treatments, more accurate diagnoses, and, ultimately, cures," said Dr. José Baselga, physician-in-chief and chief medical officer at Sloan Kettering. "If this trend of low enrollment continues, we will face a crisis in cancer research and discovery. Further education is the key to participation and progress."

Latest Headlines